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score in radical prostatectomy specimen
Shinsuke Hamada1*, Akio Horiguchi1, Kenji Kuroda1, Keiichi Ito1, Tomohiko Asano1, Kosuke Miyai1,2
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Background: Fatty acid synthase (FAS) is highly expressed in various types of cancer, and elevated expression of
FAS has been suggested to be a predictor of tumor aggressiveness and poor prognosis. We examined whether FAS
expression in prostate biopsy cores could predict the pathological characteristics of radical prostatectomy (RP)
specimens.
Methods: Paraffin-embedded prostate biopsy cores, obtained from 102 patients who subsequently underwent RP,
were immunostained with polyclonal anti-FAS antibody. The staining intensity was categorized into non-staining,
weak, moderate, and strong. Tumors with moderate or strong immunostaining were considered to show high FAS
expression, and other tumors were considered to show low FAS expression. The relation between the FAS
expression status in biopsy cores and pathological parameters in RP specimens was analyzed.
Results: The FAS expression in the biopsy cores of 64 of the 102 tumors (63%) was high, whereas it was low in the
biopsy cores of the other 38 tumors (37%). High FAS expression was significantly associated with Gleason Score
(GS) ≥ 7 in RP specimens (p< 0.0001). In multivariable logistic regression analyses, GS ≥7 in biopsy cores
(p <0.0001), higher preoperative PSA (p = 0.0194), and high FAS expression (p = 0.0004) were independent
predictors of GS ≥ 7 in the RP specimen.
Conclusions: Increased FAS expression in prostate biopsy cores could be a novel parameter for predicting higher
GS in RP specimens. The treatment strategy for patients with high FAS expression in prostate biopsy cores should
be carefully determined.
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Fatty acids are essential constitutions of all biological
membrane lipids, and are very important substrates for
energy metabolism [1]. The biosynthesis of endogenously
synthesized fatty acids is catalyzed by multifunctional
homodimeric fatty acid synthase (FAS) [1,2]. FAS is a bio-
synthetic enzyme in lipogenesis and the production of
long-chain fatty acids from acetyl-coenzyme A (Co A),
malonyl-CoA, and nicotinamide adenine dinucleotide
phosphate (NADPH) [1-3]. Under normal conditions,* Correspondence: shinsukehamaji@yahoo.co.jp
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reproduction in any medium, provided the orFAS converts excess carbohydrates into fatty acids that
are then esterified to storage triacylglycerols and pro-
vide energy through β-oxidation [1,2]. Except for liver
and adipose cells, normal cells in humans have low or
undetectable levels of expression and activity of FAS,
which is closely regulated by diet, hormones, and growth
factors [1,2].
On the other hand, FAS is highly expressed in various
types of cancer, and elevated expression of FAS has been
linked to tumor aggressiveness and poor prognosis and
reduced disease-free survival [4-6]. FAS was first identi-
fied as an oncogenic antigen 519 (OA 519) in patients
with breast cancer and a markedly poorer prognosis [7].
FAS expression is an indicator of poor prognosis inl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hamada et al. BMC Clinical Pathology 2014, 14:3 Page 2 of 6
http://www.biomedcentral.com/1472-6890/14/3breast and prostate cancers and is elevated in the blood
of cancer patients [3].
However, to the best of our knowledge, the predictive
value of FAS expressed in prostate biopsy cores has yet
to be clarified as to the clinicopathological parameters of
prostate cancer. On the basis of the studies mentioned
above, we hypothesized that the expression status of FAS
in prostate biopsies might provide valuable information
for clinicians. In this study, we performed an immunohis-
tochemical analysis of FAS expression in prostate biopsy
cores and a statistical analysis on the relationship between




This study included 102 patients (median age 67, range
51–75) who had underwent ultrasonically guided trans-
rectal and/or transperinieal prostate biopsies and radical
prostatectomies (RP) for clinically localized prostate
cancers at the National Defense Medical College from
May 1998 to April 2007. Patient characteristics are listed
on Table 1. Clinical T stage was assessed by digital rectal
examination and/or transrectal ultrasound in accordance
with the 2009 TNM classification. The Gleason grading
system for biopsies and surgical specimens was in accord-
ance with the 2005 International Society of Urological
Pathology (ISUP 2005) [8]. The positive core rate was
defined as the number of positive biopsy cores divided by
total number of biopsy cores. The levels of serum PSA
were measured on the day before the operation. Patients
who received hormonal therapy or radiation therapy priorTable 1 Patient characteristics
Parameters No. (%)
Over all 102












median (range) 8.172 (3.3-61.9)
Total biopsy cores (median) 6 -24 (8)
Positive core rate (%) (median) 5.56 -100 (25)to RP were excluded from the analysis. The follow-up
period calculated from the date of the operation to the
date of the last recorded follow-up ranged 1.0 to
149.5 months (median: 73 months). PSA failure was
considered to have occurred if PSA value was over
0.2 ng/ml after RP. We obtained informed consent for
participation in the study from participants. This study
was approved by the National Defense Medical College
ethical committee.
Immunohistochemical analyses of FAS expression in
prostate biopsy cores
Formalin-fixed, paraffin-embedded biopsy cores, 4 μm
thick, were deparaffinized in xylene and rehydrated through
graded ethanols. Endogenous peroxidase activity was
quenched with DAKO Peroxidase Blocking Reagent (Dako
Corporation) for 10 minutes. The slides were incubated
in 10% normal goat serum in PBS for 60 minutes at
room temperature. After the slides were incubated 60
minutes in a 1:50 dilution of rabbit polyclonal anti-FAS
antibody (Immuno-Biological Laboratories Co., Fujioka,
Japan) in PBS, the slides were stained by using a Simple
Stain Max PO (Nichirei Corporation, Tokyo, Japan)
according to the manufacturer’s instructions. Reaction
products were visualized by immersing the slides in
DAB for 2 minutes. The immunohistochemistry was
evaluated independently by 2 observers (K.M. and K.I.)
blinded from any clinical data. Whole biopsy slides were
evaluated in all cases examined. While comparing with
the slides of hematoxylin-eosin stain, only prostatic cancer
cells were taken into account for the evaluation of FAS
protein expression. Cytoplasmic intensities of FAS immu-
noreactivity were classified semiquantitatively into the four
categories: non-staining (negative), weak (score 1+),
moderate (score 2+), and strong (score 3+) [9,10]. When
there were heterogeneous intensities of FAS immunore-
activity within examined cases, strongest intensity was
adapted as the score of FAS expression in each case.
The staining intensity in normal prostate gland was
used as an internal control. Any discrepancies between
the assessments of the 2 observers were resolved by
conferring over a multiviewer microscope. Tumors with
3+ or 2+ immunostaining were considered high, and
other tumors were considered low. The Gleason score
(GS) in the biopsy core was determined on the same
sections.
Statistical analysis
All statistical analyses were performed by using the JMP
9.0 soft-ware system for Windows (SAS Institute Inc.
Cary, NC, USA). A chi-square test was used to assess the
association between preoperative and pathological speci-
men parameters relative to the level of FAS expression.
Logistic regression analyses were used for multivariate
Figure 1 Representative immunohistochemistry for fatty acid synthase (FAS) in prostatic adenocarcinoma. A, Case of prostatic
adenocarcinoma showing no immunoreactivity for FAS (score 0). B-D, Cases of prostatic adenocarcinoma showing weak (B), moderate (C), and
strong (D) cytoplasmic immunoreactivity for FAS, and scored as 1+, 2+, and 3+, respectively. Immunoperoxidase stain, original magnification x200
Table 2 FAS expression and preoperative parameters
FAS expression
Parameters Patients Low High P value
Clinical T stage
cT1c 71 31 40 0.0381
cT2-cT3 31 7 24
PSA (ng/ml)
≤ 10 60 24 36 0.4919
10 < 42 14 28
Needle biopsy Gleason score
≤ 6 31 18 13 0.0044
7 ≤ 71 20 51
Positive core rate (%)
≤ 40 72 33 39 0.0038
40 < 30 5 25
D’Amico risk classification
Low and Intermediate risk 67 28 39 0.1853
High risk 35 10 25
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characteristic (ROC) curves were plotted with the sensitiv-
ity (true-positive fraction) on the y-axis versus 1 minus the
specificity (false-positive fraction) on the x-axis. The PSA
failure rate was calculated and compared by log-rank test-
ing. P values less than 0.05 were considered to indicate
statistical significance.
Results
Relations between FAS expression in biopsy cores and
preoperative parameters
We first evaluated the expression level of FAS in prostate
biopsy cores. FAS expression was high in the biopsy cores
of 64 of the 102 tumors (63%) and low in the other 38
tumors (37%): 4 (4%) showing negative immunostaining,
34 (33%) showing 1+ immunostaining (weak staining),
44 (43%) showing 2+ immunostaining (moderate staining),
20 (20%) showing 3+ immunostaining (strong staining)
(Figure 1). Table 2 lists the p values for the associations
between FAS status and preoperative parameters. High
FAS expression was significantly associated with clinical
T stage (cT2-cT3) (p =0.0381), GS ≥ 7 in the biopsy core
(p = 0.0044) and positive core rate > 40% (p = 0.0038).
Preoperative parameters including PSA and D’Amico
risk classification [11] were not associated with FAS
expression status (Table 2).
Relations between FAS expression and pathological
parameters of RP specimens
Next, we analyzed the association between FAS expres-
sion in the biopsy cores and pathological features of RPspecimens. High FAS expression was significantly asso-
ciated with GS ≥7 in the RP specimens (p< 0.0001,
Table 3). However, high FAS expression was not signifi-
cantly associated with any other pathological parameters,
including status of extraprostatic extention, lymphatic inva-
sion, microvessel invasion, or perineural invasion. Although
high FAS expression in biopsy cores was significantly asso-
ciated with positive core rate > 40%, it was not associated
with maximum tumor diameter in RP specimens.
Table 3 FAS expression and pathological parameters
FAS expression
Parameters Patients Low High P value
Gleason score
≤ 6 23 18 5 < 0.0001
7 ≤ 79 20 59
Extra-prostatic extension
Positive 45 14 31 0.3002
Negative 56 23 33
Lymphatic invasion
Positive 51 18 33 0.6821
Negative 51 20 31
Microvascular invasion
Positive 40 13 27 0.4232
Negative 62 25 37
Perineural invasion
Positive 71 23 48 0.0978
Negative 30 15 15
Maximum tumor size
≤ 10 mm 13 6 7 0.4823
10 mm < 89 32 57
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predictor of GS ≥ 7 in RP specimens
The ability to predict GS in RP specimens using pre-
operative parameters is quite important for the selection
of therapies for localized prostate carcinoma [12,13]. On
the basis of our results, we examined whether the FAS
expression in biopsy cores could be a novel preoperative
predictor of higher GS in the RP specimens. In the univar-
iate analysis, preoperative parameters including clinical T
stage, GS ≥7 in biopsy cores, PSA, positive core rate, and
high FAS expression in biopsy cores were significantly as-
sociated with GS ≥7 in RP specimens. In the multivariable
logistic regression analyses, biopsy GS ≥ 7 (p < 0.0001), in-
creasing preoperative serum PSA level (p = 0.0202), and
high FAS expression (p = 0.0012) were independent pre-
dictors of GS ≥ 7 in RP specimens (Table 4).Table 4 Univariate and multivariate analyses to predict speci
Univaria
P value Odds rat
FAS expression in biopsy cores (Low vs. High) < 0.0001 10.62
Clinical T stage (cT1 vs. cT2 ≤) 0.0293 3.66
Needle biopsy Gleason score ( ≤ 6 vs. 7≤) < 0.0001 72.45
PSA (ng/ml) 0.0174 1.09
Positive core rate (%) (≤ 40% vs. 40% <) 0.007 5.76
Total biopsy cores (≤ 8 vs. 8 <) 0.4131 1.48ROC analyses
The area under the ROC curve (AUC) was calculated
(Figure 2) as a way to estimate the predictive value of the
preoperative parameters for RP specimens with GS ≥7.
AUC was 0.6277 for PSA, 0.9062 for needle biopsy GS,
0.6263 for clinical T stage, 0.8079 for D’Amico risk classifi-
cation, and 0.7933 for FAS expression. In particular, the
AUC of the combination of FAS and GS ≥7 in the biopsy
cores reached 0.9623.
FAS expression and the period to PSA failure
The Kaplan-Meier survival curves for PSA fairure rate is
shown in Figure 3, where they are stratified by FAS
expression. Although patients with high FAS expression
tended to have high PSA failure rates compared with those
with low FAS expression, it did not reach statistically
significant (p = 0.1028).
Discussion
Fatty acids are synthesized to provide lipids for energy
production via β-oxidation and lipid modification of pro-
teins and membrane formation in cancer cells [1-3]. FAS
is highly expressed in many cancers, including thyroid,
oral, tongue, esophageal, lung, breast, endometrial, ovar-
ian, colorectal, bladder, hepatocellular, pancreatic and
gastric carcinomas, as well as sarcoma, Paget’s disease of
the vulva, gastrointestinal stromal tumor, and multiple
myeloma [1-3,14-16]. Regarding urological malignancies,
increased expression and its association with tumor ag-
gressiveness and poor cancer-specific survival are evident
in patients with prostate and kidney cancer [9,17-19].
The relationship between FAS and prostate cancer has
been widely investigated. FAS was over-expressed in
high grade prostatic epithelial neoplasia (PIN), and FAS
expression was found to be possibly one of the earliest
events in the development of prostate cancer [9]. FAS
expression was also a strong independent predictor of
pathologic stage [17]. While FAS expression in benign
tissue was reduced after androgen ablation, it persisted
in human prostate carcinoma after androgen ablation and
was high in 82% of lethal tumors examined by autopsy
[18]. Increased FAS expression appeared to increase themen Gleason score ≥ 7
te Multivariate
io 95% CI P value Odds ratio 95% CI
3.71-35.65 0.0012 34.15 3.42 - 1145.4
1.13-16.49 0.4890 2.29 0.23 - 32.36
17.84-499.7 < 0.0001 228.17 25.37 - 8358.31
1.01-1.19 0.0202 1.22 1.03 -1.57
1.53-37.7 0.9106 1.14 0.10 - 10.95










FAS: 0.7933cT: 0.6263 FAS+biopsy GS: 0.9623
D’Amico risk 
classification: 0.8079
Figure 2 Receiver operating characteristic (ROC) curves and areas under the ROC curves (AUC) of PSA, biopsy Gleason score, D’Amico
risk classification, clinical T stage, FAS expression, and needle biopsy Gleason score added to FAS expression for predicting RP
specimen Gleason score ≥7.
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be used as a prostate cancer marker, and anti-neoplastic
therapy based on FAS inhibitions may be an option for
chemo prevention or curative treatment of nearly all
prostate cancers [9]. These observations suggest that
FAS expression status could be an important parameter
of tumor aggressiveness and in prostate cancer. Al-
though the mechanism of cell malignant transformation
or cell proliferation induced by FAS over expression in
malignant tumor is not fully understood, several mecha-
nisms including increasing expression of epidermal growth
factor receptor and activation of PI3K/AKT and ERK1/2
signaling pathways, and the modulation and nuclearLow FAS expression 
High FAS expression 












Figure 3 Kaplan-Meier curves for PSA failure rates after RP in
patients with high and low FAS expression.maturation of the transcription factor sterol regulatory
element-binding protein 1c have been reported [1-3].
Most of the studies on FAS expression in prostate cancer
examined RP specimens, and a few studies focused on FAS
expression in biopsy cores [4,6,9,17,18]. Bandyopadhyay
et al. and Swinnen et al. reported that FAS expression
levels in prostate cancer specimens including needle
biopsies were correlated with the degree of Gleason
grade [6,9]. In our study’s results, high FAS expression
in biopsy cores was significantly associated with biopsy
cores GS ≥7, which is consistent with previous observa-
tions [6,9]. We therefore speculated that the expression
status of FAS in the biopsy core could be a novel diag-
nostic tool for evaluating tumor aggressiveness in pros-
tate cancer. The decision of which treatment to pursue
in clinically localized prostate cancer depends on the
aggressiveness of the tumor. GS in biopsy cores is one
of the most valuable parameters of tumor aggressive-
ness. The ability to assign a precise GS in the prostate
is quite important for selecting appropriate treatments
for prostate cancer. However, the GS values in about
40–50% of RP specimens do not correspond with those
calculated from needle biopsies [12,13,20]. Various param-
eters including patient age, PSA, maximum percentage
cancer/biopsy cores, the number of biopsy cores and sur-
gical specimen weight have been shown to be useful for
precisely predicting GS [12,20] in RP specimens, but none
has proven to be definitive. In our study, high FAS expres-
sion of biopsy cores was an independent predictor of RP
specimens GS≥7 in addition to GS of biopsy cores. In
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in biopsy cores reached 0.9623.
Our studies have some limitations. Although we ana-
lyzed the relationship between FAS expression and the
period to PSA failure, there was no significant association
between the parameters. We consider that the underlying
reasons include insufficient numbers of patients and RPs
performed by variety of surgeons with different skills. We
could not analyze the relationship between nutritional sta-
tus and FAS expression levels. In recent study, it has been
reported that overweight prostate cancer patients tend to
have germline single nucleotide polymorphisms (SNPs) in
the FAS gene and FAS tumor expression, suggesting FAS
might play the key role in poor outcome in obese prostate
cancer patients [21]. Despite such limitations, our results
provide novel information about biopsy cores for precisely
predicting GS.
Conclusions
Increased FAS expression in prostate biopsy cores could
be a novel parameter for predicting higher GS in RP speci-
mens. The treatment strategy for patients with high FAS
expression in prostate biopsy cores should be carefully
determined.
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